Latest immunotherapies Stories
SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
IPSWICH, Mass., April 28, 2014 /PRNewswire/ -- New England Biolabs (NEB(®)) announces that it has been awarded a $250,000 grant from the Massachusetts Life Sciences Center (MLSC) to
Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology
Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine,
MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting
-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors.
AMSTERDAM, February 11, 2014 /PRNewswire/ -- - SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the
- A poem in which the author retracts something said in an earlier poem.